<DOC>
	<DOC>NCT02548585</DOC>
	<brief_summary>A Phase 1/2, multiple dose study with 6 cohorts of ascending doses designed to evaluate the efficacy, safety and pharmacokinetics (PK) of MEDI0382 in patients with Type 2 Diabetes Mellitus (T2DM).</brief_summary>
	<brief_title>A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo controlled study designed to evaluate the efficacy, safety, and PK of MEDI0382 administered as multiple daily SC doses to subjects with T2DM. Approximately one hundred and seven subjects will be enrolled across 6 cohorts. In cohorts 1-3 the subjects will be randomized to MEDI0382 or placebo (3:1). In Cohort 4, subjects will be randomized 1:1. In cohort 5 and 6 subjects will be randomized to MEDI0382 or placebo (3:1).</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Diagnosis of T2DM, ages 1865 Must provide written informed consent BMI &gt;27 and &lt;40 kg/m2, inclusive Venous access suitable for multiple cannulations Vital signs within normal specified ranges Females must be nonlactating and nonchildbearing potential Males must practice 2 effective contraceptive measures if sexually active Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs History of cancer within the last 10 years, with the exception of nonmelanoma skin cancer Any clinically important illness (except for T2DM), medical/surgical procedure, or trauma within 4 weeks prior to dosing Fasting glucose â‰¥ 200 mg/dL Positive Hepatitis B, Hepatitis C or HIV test or use of antiretroviral medications at screening. Concurrent or previous use of a GLP1 receptor agonist Current or previous use of systemic corticosteroids within the past 28 days prior to screening Use of any medicinal products or herbal preparations licensed for control of body weight or appetite is prohibited. Known or suspected history of alcohol or drug abuse within the past 3 years. Positive drug screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEDI0382, diabetes</keyword>
</DOC>